<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00464399</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001ANO01</org_study_id>
    <nct_id>NCT00464399</nct_id>
  </id_info>
  <brief_title>Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients</brief_title>
  <official_title>A Pilot Study to Evaluate Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of early switch to everolimus from cyclosporine A in&#xD;
      de novo renal transplant recipients by assessing rejection rate everolimus trough levels,&#xD;
      other safety laboratory variables and adverse events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biopsy proven acute rejections or treatment for acute rejections from the time of the conversion from cyclosporine based regimen to a cyclosporine free treatment with everolimus 7 weeks ± 7 days after transplantation until completion of 7 weeks after</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by graft and patients survival from the time of conversion 7 weeks ± 7 days until the end of follow-up 12 months after transplantation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics assessed by blood samples for everolimus concentration , cyclosporine concentrations</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by blood sampling for Hemoglobin, white blood cells (WBC), platelets, s-creatinine, ASAT, ALAT, ALP bilirubin, S-Na, S-K, S-Ca, S-P. S-Urea, S-creatin phosphokinase (S-CPK), u-alb/creatinine ratio</measure>
  </secondary_outcome>
  <enrollment>20</enrollment>
  <condition>De Novo Renal Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged above 18 years.&#xD;
&#xD;
          -  Patients having received their first or second single renal transplant from deceased&#xD;
             or living donor&#xD;
&#xD;
          -  Patient willing and capable of giving written informed consent for study participation&#xD;
&#xD;
          -  Patients treated with as induction therapy at the time of transplantation&#xD;
&#xD;
          -  Patients maintained on a triple immunosuppressive regime consisting of cyclosporine&#xD;
             (C-0 h between 100-250 ng/ml or a C-2 h between 900-1100 ng/ml), Enteric coated&#xD;
             mycophenolate sodium (EC-MPS), minimum dose 1080 mg and corticosteroids, minimum dose&#xD;
             10 mg&#xD;
&#xD;
          -  Patients without any biopsy proven acute rejection episode or treatment for any acute&#xD;
             rejection since the transplant&#xD;
&#xD;
          -  Females capable of becoming pregnant must have a negative pregnancy test prior to the&#xD;
             switch to everolimus and are required to practice a medically approved method of birth&#xD;
             control for the duration of the study and a period of 8 weeks following&#xD;
             discontinuation of study medication, even where there has been a history of&#xD;
             infertility.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recipient of multi-organ transplants, and or previously transplanted with any other&#xD;
             organ different from a kidney transplant&#xD;
&#xD;
          -  Patients with antibodies towards the donor kidney above 30%&#xD;
&#xD;
          -  Patients receiving a renal transplant from HLA-identical sibling&#xD;
&#xD;
          -  Presence of hyper sensitivity to drugs similar to everolimus ( e.g. macrolides)&#xD;
&#xD;
          -  Patient with past (within the last two years) or present malignancy other than excised&#xD;
             basal cell or squamous cell carcinoma of the skin&#xD;
&#xD;
          -  Patients who are recipients of AB0 incompatible transplants&#xD;
&#xD;
          -  Patients with unsuitable laboratory values&#xD;
&#xD;
          -  Patients with ongoing wound healing problems or other severe surgical complication in&#xD;
             the opinion of the investigator&#xD;
&#xD;
          -  Patient with a current severe major local or systemic infection&#xD;
&#xD;
          -  Patients requiring dialysis and/or having a calculated glomerular filtration rate&#xD;
             (Cockcroft-Gault) &lt; 20 ml/min&#xD;
&#xD;
          -  Presence of intractable immunosuppressant complications or side effects (e.g., severe&#xD;
             gastrointestinal adverse events) at the time of the switch&#xD;
&#xD;
          -  Patients who are HIV positive or Hepatitis B surface antigen positive or Hepatitis C&#xD;
             virus positive. Recipients of organs from donors who test positive for Hepatitis B&#xD;
             surface antigen or Hepatitis C are excluded.&#xD;
&#xD;
          -  Evidence of severe liver disease&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site,</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Holdaas H, Bentdal O, Pfeffer P, Mjørnstedt L, Solbu D, Midtvedt K. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant. 2008 May-Jun;22(3):366-71. doi: 10.1111/j.1399-0012.2008.00795.x. Epub 2008 Feb 12.</citation>
    <PMID>18279419</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>April 19, 2007</study_first_submitted>
  <study_first_submitted_qc>April 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2007</study_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>De novo renal transplantation</keyword>
  <keyword>CNI-free protocol</keyword>
  <keyword>adults</keyword>
  <keyword>everolimus</keyword>
  <keyword>rejections</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

